Kennedy Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Kennedy Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,435	Closed	-$741K	–	716
2020 Q3	$741K	Sell	13,435 -8,424	-39%	-$535K	0.02%	570
2020 Q2	$1.38M	Buy	21,859 +153	+0.7%	+$10.5K	0.04%	548
2020 Q1	$1.11M	Buy	21,706 +2,943	+16%	+$197K	0.04%	549
2019 Q4	$1.49M	Sell	18,763 -701	-4%	-$41.5K	0.04%	583
2019 Q3	$944K	Sell	19,464 -1,262	-6%	-$65.8K	0.02%	597
2019 Q2	$1.09M	Buy	+20,726	New	+$1.19M	0.03%	595

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Kennedy Capital Management's GBT Position: Q4 2020 in Review

Kennedy Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 13,435 shares — an estimated $741K sold.

Kennedy Capital Management first reported a position in GBT in Q2 2019 and held it in 6 quarters. The position peaked at $1.49M in Q4 2019. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

Kennedy Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Kennedy Capital Management sold 13,435 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $741K.
Kennedy Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 6 quarters.
Kennedy Capital Management's Global Blood Therapeutics, Inc. position peaked at $1.49M in Q4 2019.
228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Kennedy Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.